Regeneron Pharmaceuticals, Inc. (LON: 0R2M)
London
· Delayed Price · Currency is GBP · Price in USD
687.82
+2.15 (0.31%)
Jan 22, 2025, 7:07 PM BST
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 13,450 employees as of December 31, 2023. The number of employees increased by 1,599 or 13.49% compared to the previous year.
Employees
13,450
Change (1Y)
1,599
Growth (1Y)
13.49%
Revenue / Employee
729.36K GBP
Profits / Employee
245.16K GBP
Market Cap
59.41B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Regeneron Pharmaceuticals News
- 13 hours ago - Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action - PRNewsWire
- 14 hours ago - Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky - Accesswire
- 15 hours ago - ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN - GlobeNewsWire
- 17 hours ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN - Accesswire
- 17 hours ago - REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewsWire
- 19 hours ago - Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky - Accesswire
- 19 hours ago - ROSEN, NATIONAL TRIAL LAWYERS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN - Accesswire
- 19 hours ago - Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman - GlobeNewsWire